Search
HeartSciences Inc
HSCSAdd to Watchlist
2.790USD
-0.150-5.10%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
8.88MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-5.10%
5 Days
-5.10%
1 Month
+38.81%
6 Months
-11.15%
Year to Date
-9.71%
1 Year
-21.85%
Key Figures
2.828Open
2.930High
70.76KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.22%Turnover Ratio
2.940Prev. Close
2.728Low
157.93KTurnover
LossP/E Static
3.35P/B
0.00%Div Yield TTM
-128.00%ROA
6.47052wk High
0.54Volume Ratio
-8.77MNet Profit
3.18MShares
-4.4856EPS TTM
2.01Beta
-382.43%ROE
1.75052wk Low
6.86%Amplitude
59.06%Gross Margin
8.88MMarket Cap
8.54Reward/Risk
5.42%Risk Rate
TradingKey Stock Score of HeartSciences Inc
Currency: USD Updated: 2026-07-02Key Insights
HeartSciences Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 127 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
HeartSciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
HeartSciences Inc Highlights
StrengthsRisks
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.35K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.35K.
Undervalued
The company’s latest PE is -0.62, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 198.36K shares, decreasing 10.34% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 13.44.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
10.000
Target Price
+240.14%
Upside Space
HeartSciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
HeartSciences Inc Info
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
Ticker SymbolHSCS
CompanyHeartSciences Inc
CEOSimpson (Andrew)
Websitehttps://heartsciences.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of HeartSciences Inc (HSCS)?
The current price of HeartSciences Inc (HSCS) is 2.79.
What is the symbol of HeartSciences Inc?
The ticker symbol of HeartSciences Inc is HSCS.
What is the 52-week high of HeartSciences Inc?
The 52-week high of HeartSciences Inc is 6.47.
What is the 52-week low of HeartSciences Inc?
The 52-week low of HeartSciences Inc is 1.75.
What is the market capitalization of HeartSciences Inc?
The market capitalization of HeartSciences Inc is 8.88M.
Is HeartSciences Inc (HSCS) currently rated as Buy, Hold, or Sell?
According to analysts, HeartSciences Inc (HSCS) has an overall rating of Buy, with a price target of 10.00.
What is the Earnings Per Share (EPS TTM) of HeartSciences Inc (HSCS)?
The Earnings Per Share (EPS TTM) of HeartSciences Inc (HSCS) is -9.34.